PD-L1 negative

Encouraging results in non-clear cell RCC. However, efficacy appears to be lower in the chromophobe subtype and in the PDL1-negative group. In the chromophobe type, lenvatinib + everolimus may be more effective. (@dr_yakupergun)

#radonc after another patient with PD-L1 negative squamous cell LUL #lungcancer and 4L N2 getting CM816 regimen😅 @FordePatrick @KatieKeaneMD https://t.co/iRoM58oSHF (@HenningWillers)

#radonc after another patient with PD-L1 negative squamous cell LUL #lungcancer and 4L N2 getting CM816 regimen😅 @FordePatrick https://t.co/iRoM58oSHF (@HenningWillers)

#radonc after another patient with PD-L1 negative squamous cell LUL #lungcancer and 4L N2 getting CM816 regimen😅 @FordePatrick @KatieKeaneMD @JustinGainor https://t.co/iRoM58oSHF (@HenningWillers)

HPV Advances: Dr. @DrJaredWeiss discusses treatment options for patients with head and neck cancer who have a low (below 20) or negative PD-L1. https://t.co/UquZHLFuTO (@cancerGRACE)

Some provocative discussions at #RomeLung23 on adjuvant immunotherapy in PDL1 negative NSCLC @FedericoCappuz1 @LuisPaz_Ares @delvysra @EnriquetaFelip @ThomasW35874311 (@StephenVLiu)

PDL1 negative #LCSM is a challenger disease. More #clinicaltrials are needed in this setting. In this weekend I talk about therapy available in my country and the gap between public and private care (the dead valley). Beyond later diagnosis, access to new drugs are scarce 🥹 (@FernandoOnco)

Dr. @FordePatrick at #RomeLung23 discusses how PDL1 could influence perioperative immunotherapy for NSCLC. Do we need chemo for PDL1 high? (worth studying) Should we give neoadjuvant IO in PDL1 negative cases? (yes if giving chemo) #LCSM (@StephenVLiu)

📊 Pembro for all is the poll favorite Personally, I remain less inclined to offer adjuvant pembro for patients with PDL1 negative disease. #lcsm https://t.co/GhEctGRLK2 (@esinghimd)

The benefit of pembrolizumab in Pd-l1 negative NSCLC @CharuAggarwalMD @DrSteveMartin @deeptibehl1 https://t.co/E1ewd3WDY1 (@oncologician)

As presented by Dr. @peters_solange at #ESMO22, adjuvant pembrolizumab had a DFS HR 0.82 in PDL1 high, 0.67 in PDL1 low and 0.78 in PDL1 negative. Different from IMpower 010 where greatest benefit was in PDL1 high subset (DFS HR 0.43), which aligns more to expectations. #LCSM (@StephenVLiu)

Promising approach in upfront PDL-1 negative TNBC. (@abhenilmittal)

Role of IO in LABC ( TNBC ) in PDL 1 negative tumors...? 🙏 (@myfight4cancer)

Avelumab/axitinib in B3 thymoma & thymic carcinoma (CAVEATT) N=32 (thymic carcinoma majority) ORR=34% Similar PFS between between PD-L1 high vs. PD-L1 low/negative is notable Incidence of serious irAEs=12% (similar to PD-1 monoTx) @TheLancetOncol https://t.co/LQL8ueEWJQ (@chulkimMD)

Very clinically helpful and nuanced discussion of management of PDL1 negative lung cancer. I really enjoyed this one. Thank you ⁦@HosseinBorghaei⁩ ⁦@StephenVLiu⁩ Dr Reyes Barnabe Caro https://t.co/nRnAg2T9Of (@LeciaSequist)

Fox Chase’s Dr. @HosseinBorghaei joins Dr. Bernabe and host @StephenVLiu for a discussion on the management of metastatic, PDL1 negative NSCLC NSCLC on Lung Cancer Considered. Listen now: https://t.co/BSLMiGG04j @IASLC (@FoxChaseCancer)

In this virtual tumor board episode of #LungCancerConsidered, the official @IASLC podcast, I discuss management of advanced PD-L1 negative NSCLC with Drs. @HosseinBorghaei and Reyes Bernabe Caro. #LCSM https://t.co/tT8wdXE7A3 (@StephenVLiu)

Host @StephenVLiu leads a discussion on the management of metastatic, PDL1 negative #NSCLC with @HosseinBorghaei, Chief of Thoracic Oncology at @FoxChaseCancer, & Dr. Reyes Bernabe Caro, Section Chief of Medical Oncology at @UGTHUVRocio. Listen Now: https://t.co/aV6zfCYkzV #LCSM (@IASLC)

Tune in next week for a virtual tumor board on #LungCancerConsidered, the official @IASLC podcast, where I discuss management of advanced PDL1 negative NSCLC with Drs. Reyes Bernabe Caro and @HosseinBorghaei. #LCSM https://t.co/Uyom7qDQWF (@StephenVLiu)

Agree. Benefit in PD-L1+ is mainly driven by PD-L1>50% subgroup (again with caution as this is a no formal stat test at an IA in a subgroup). Impactful to me to see that atezolizumab could be even harmful in PD-L1 negative. #WCLC22 #lcsm (@Tony_Calles)

Interim OS analysis of IMpower010, adjuvant Atezolizumab in resected NSCLC presented at #WCLC2022 👉 no significant OS difference 👉 trend to improved OS in PD-L1 pos, especially in min 50% 👉 no signal for benefit in PD-L1 negative patients (@Mat_Guc)

PDL1 expression and #mesothelioma: hot topic. Both @IbiayiMD and @AMansfieldMD (joining remotely) agree that PDL1 status is not currently predictive of IO benefit and PDL1 negative tumors should still receive IO. Agree fully: evidence based conclusion. #WCLC22 (@DrSanjayPopat)

Hi there, is there any immunotherapy for HER2 negative breast cancer , PDL1 is Negative, what is the best treatment, my wife is very sick. (@AVESHT1)

#ASCO22 Abstract #9003 looks intriguing. Eftilagimod alpha (soluble LAG-3 protein, subQ) plus pembro for 1L NSCLC showed RR 37% including 55% in PDL1 high and 27% in PDL1 negative NSCLC. Hope to see data on durability in oral presentation to be given by Dr. @EnriquetaFelip. #LCSM (@StephenVLiu)

I really agree w/you: CPS<5👉+ IO just for ⬆️ORR! Although, we recently discussed a rare case of gastric cancer with CNS metastasis + PDL-1 negative (& good PS)😊Despite the neg PDL-1, we suggest chemo+IO based on this interesting Korean case report: https://t.co/CoBmKJW5jd (@KellyBorgesAra2)

While all still reviewing/processing exciting data, in my first look, not sure patients with negative PDL-1 #NSCLC are benefiting much (similar to what we saw in adjuvant atezo data) (@RManochakian)

51 years old, female, uT2N0m0 stomach cancer 1.5cm. MSS, her2 negative, PDL1 CPS-3. Perioperative CT - four cycles of FLOT. Gastrectomy - 0.3 cm residual disease, ypT1b, 41 lymph nodes negatives. What would you recomend ? @YJanjigianMD @duiliorocha_onc @AnelisaCoutinh1 Tks. (@pam65230529)

But still, based on PACIFIC, we would expect a benefit of consolidation IO in this setting even for patients with PDL1 negative status #LCSM (@CharuAggarwalMD)

Similar situation now with a 50 yo male former smoker, no other comorbidities. lung adenocarcinoma, EGFR/ALK negative, PD-L1 20%. Stage IIIB (T4N2 by 7th and 8th AJCC Ed) VATS RUL lobectomy after neoadjuvant chemo-IO. pCR Remains NED (cc’d @DoctorJSpicer: again no N2 pics 🙏) (@Tony_Calles)

What is your first line treatment option for metastatic fibrolamellar HCC? Child-Pugh A5. Molecular profiling showed MSS, negative PD-L1 and low TMB at 2. No NTRK fusion. DNAJB1 pathogenic fusion and TERT promoter pathogenic variant @GABOUALFA @GIcancerDoc @pashtoonkasi (@m_khushman)

#SABCS2021 Nimbus results: 30 pts accrued, 21 HR+ and 9 TNBC. Most were PD-L1 negative, and median TMB was 10.9. 5 patients had confirmed response and 6 SD. CBR was seen in 5 pts. 3/5 responders were ER pos and only 1 was PD-L1 pos. TMB >/= 14 in 3/5 responders. MDR 12.1 mo. (@GeorgeSledge51)

It can be approved by private insurers after a peer to peer. For Medicare, it is listed in the NCCN guidelines for PDL1 negative, driver negative NSCLC as a Category 2A. Not positive about the current policy of CMS on NCCN 2A recs. (@StephenVLiu)

4 year OS of 24% in PDL1 negative patients is amazing, is there no plan to prove this in a trial the FDA would accept? Right now we can't use this combo in that population, or am I wrong, is anyone using (and getting coverage) for off-label nivo/ipi in PDL1 <1%? #LCSM (@n8pennell)

#ESMO21 Median time to initiation of durvalumab was 56 days (which is quite real-world). Median duration of therapy was 11 months (of the planned 12 months). 73% were PDL1 positive, 18% PDL1 negative but PDL1 not tested for 432 patients. #LCSM @myESMO (@StephenVLiu)

#ESMO21 mPFS by subgroup including PDL1 with mPFS in PDL1 positive of 22.4m and PDL1 negative of 16.3m. Outcomes better for non-squamous, as expected. Also included pts receiving sequential chemoradiation and mPFS of 19.4m encouraging. Helpful data here. #LCSM @myESMO (@StephenVLiu)

.@JulieBrahmer offers a really nice perspective on use of IO in 1L mNSCLC ✴️ D+CT not better for OS ✴️ D+T+CT improves PFS, OS c/w CT ✴️Probably relevant in PDL1 negative population #LCSM #WCLC21 @IASLC (@CharuAggarwalMD)

Do you have any research por TNBC with negative PDL1 biomarkers? (@VERONICABASA)

What is the real impact of immunotolerance in patients with NSCLC and intermediate or negative PDL1 exposed to regimens such as 9LA, 227 or Poseidon? (@AndresFCardonaZ)

#ASCO21 Looking at subgroups of the all-randomized stage II-IIIA dataset, we see greater DFS benefit for PDL1 high (TC, SP263) with HR 0.43 compared to 0.66 for PDL1 positive and 0.97 for PDL1 negative. What we need to see is PDL1 low (1-49%). #LCSM (@StephenVLiu)

#ASCO21 The benefit for OS, PFS and DOR was seen across all PDL1 strata (PDL1 negative, positive and high), consistent with chemo/IO approaches in other studies. Again, no maintenance chemotherapy here so important to follow up as done here. #LCSM (@StephenVLiu)

#ASCO21 Breakdown of PACIFIC by PDL1 status. Notable fraction of patients unknown PDL1 and the positive vs negative comparison was not predefined. But in that post-hoc analysis, PDL1 negative cohort did not fare as well with durvalumab. PDL1 part of EMA label, not US label. #LCSM (@StephenVLiu)

#MedTwitter #pcsm #PancreaticCancer colleagues: Any active trials or ideas based on these genomics 🧬 pMMR, TMB 3 Mut/Mb and PD-L1 negative; exhausted all SoC but exceptional responder since diagnosis in 2016 @EileenMOReilly @Dr_R_Kurzrock @ShaalanBeg @MPishvaian @VivekSubbiah (@DrBonillaOnc)